[go: up one dir, main page]

WO2005076012A3 - Nouveaux variants d'epissure et methodes d'utilisation associees - Google Patents

Nouveaux variants d'epissure et methodes d'utilisation associees Download PDF

Info

Publication number
WO2005076012A3
WO2005076012A3 PCT/US2005/002695 US2005002695W WO2005076012A3 WO 2005076012 A3 WO2005076012 A3 WO 2005076012A3 US 2005002695 W US2005002695 W US 2005002695W WO 2005076012 A3 WO2005076012 A3 WO 2005076012A3
Authority
WO
WIPO (PCT)
Prior art keywords
splice variants
methods
novel splice
polypeptides
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/002695
Other languages
English (en)
Other versions
WO2005076012A2 (fr
Inventor
Keting Chu
Amy L Tsui Collins
Ernestine Lee
Justin G P Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Five Prime Therapeutics Inc
Original Assignee
Five Prime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc filed Critical Five Prime Therapeutics Inc
Publication of WO2005076012A2 publication Critical patent/WO2005076012A2/fr
Publication of WO2005076012A3 publication Critical patent/WO2005076012A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des variants d'épissure de polypeptides qui sont considérablement exprimés dans des tissus tumoraux. De tels polypeptides sont utilisés à des fins thérapeutiques, diagnostiques et prophylactiques. Notamment, lesdits polypeptides sont utilisés en tant que cibles pour le développement de modulateurs dans le traitement de maladies.
PCT/US2005/002695 2004-01-30 2005-01-31 Nouveaux variants d'epissure et methodes d'utilisation associees Ceased WO2005076012A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54074504P 2004-01-30 2004-01-30
US60/540,745 2004-01-30

Publications (2)

Publication Number Publication Date
WO2005076012A2 WO2005076012A2 (fr) 2005-08-18
WO2005076012A3 true WO2005076012A3 (fr) 2006-02-16

Family

ID=34837419

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/002695 Ceased WO2005076012A2 (fr) 2004-01-30 2005-01-31 Nouveaux variants d'epissure et methodes d'utilisation associees

Country Status (1)

Country Link
WO (1) WO2005076012A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0519376D0 (en) * 2005-09-23 2005-11-02 Astrazeneca Ab Diagnostic method
CN116284224B (zh) * 2023-05-12 2023-07-25 中国农业大学 一种结合Claudin 18.2的环肽及其应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999033979A2 (fr) * 1997-12-30 1999-07-08 Chiron Corporation Proteines secretees par la moelle osseuse et polynucleotides
US5968744A (en) * 1997-10-14 1999-10-19 Incyte Pharmaceticals, Inc. Human cornichon molecule
WO2001077289A2 (fr) * 2000-04-06 2001-10-18 Genetics Institute, Llc. Polynucleotides codant de nouvelles proteines secretees
WO2003042357A2 (fr) * 2001-09-28 2003-05-22 Incyte Genomics, Inc. Enzymes
EP1347046A1 (fr) * 2002-03-22 2003-09-24 Research Association for Biotechnology Séquences d'ADN complémentaire entières
US20030211096A1 (en) * 1999-08-31 2003-11-13 Genentech, Inc. Compositions and methods for the treatment of tumor
WO2004023973A2 (fr) * 2002-09-12 2004-03-25 Incyte Corporation Molecules utilisees a des fins diagnostiques et therapeutiques

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968744A (en) * 1997-10-14 1999-10-19 Incyte Pharmaceticals, Inc. Human cornichon molecule
WO1999033979A2 (fr) * 1997-12-30 1999-07-08 Chiron Corporation Proteines secretees par la moelle osseuse et polynucleotides
US20030211096A1 (en) * 1999-08-31 2003-11-13 Genentech, Inc. Compositions and methods for the treatment of tumor
WO2001077289A2 (fr) * 2000-04-06 2001-10-18 Genetics Institute, Llc. Polynucleotides codant de nouvelles proteines secretees
WO2003042357A2 (fr) * 2001-09-28 2003-05-22 Incyte Genomics, Inc. Enzymes
EP1347046A1 (fr) * 2002-03-22 2003-09-24 Research Association for Biotechnology Séquences d'ADN complémentaire entières
WO2004023973A2 (fr) * 2002-09-12 2004-03-25 Incyte Corporation Molecules utilisees a des fins diagnostiques et therapeutiques

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 29 August 2003 (2003-08-29), XP002346302, retrieved from EBI Database accession no. CF374855 *
DATABASE EMBL [online] 6 September 2001 (2001-09-06), XP002346301, retrieved from EBI Database accession no. BI559784 *

Also Published As

Publication number Publication date
WO2005076012A2 (fr) 2005-08-18

Similar Documents

Publication Publication Date Title
WO2004113571A3 (fr) Genes specifiques de la prostate et leur utilisation comme cibles dans le traitement et le diagnostic du cancer de la prostate
WO2004092215A3 (fr) Methodes therapeutiques utilisant des agents liants specifiques de l'angiopoietine-2 humaine
EP2759302A3 (fr) 4F-benzoyl-TN14003 combiné avec rituximab pour une utilisation dans le traitement d'une tumeure
WO2009070294A3 (fr) Inhibition du récepteur de la protéine stimulant les macrophages (ron) et procédés de traitement
WO2006050058A3 (fr) Methodes de detection et de therapie de tissus enflammes par immunomodulation
WO2010017196A3 (fr) Anticorps monoclonaux contre l'inhibiteur de la voie du facteur tissulaire (tfpi)
WO2007044026A3 (fr) Compositions comportant du collagène modifié et leurs utilisations
WO2005120461A3 (fr) Formulations liposomales renfermant de la dihydrosphingomyeline, et procedes d'utilisation correspondants
WO2010057112A3 (fr) Variants génétiques intervenant dans la cognition humaine et leurs procédés d'utilisation comme cibles diagnostiques et thérapeutiques
WO2006058868A8 (fr) Pteridines substituees destinees au traitement de maladies inflammatoires
WO2004112829A3 (fr) Compositions et procedes pour le diagnostic et le traitement de tumeurs d'origine gliale
WO2008076954A3 (fr) Composés hétérocycliques et procédés d'utilisation de ceux-ci
WO2003072593A3 (fr) Peptides ciblant les os
EP2175879A4 (fr) Traitement de maladies associées à la protéine prion
WO2006099610A3 (fr) Methodes d'identification de cibles therapeutiques pour le traitement de l'atrophie vulvovaginale
WO2006113483A3 (fr) Methodes et compositions pour le traitement ou la prevention du cancer
WO2005003154A8 (fr) Compositions et methodes de diagnostic et de traitement de tumeur
WO2007111661A3 (fr) anticorps humains specifiques a des matieres et des procedes a base de gastrine
AU2003237792A1 (en) Compositions and methods for the diagnosis and treatment of tumor
EA201070195A1 (ru) ПРОИЗВОДНЫЕ 1,2,3,4-ТЕТРАГИДРОПИРРОЛО [1,2-А]ПИРАЗИН-6-КАРБОКСАМИДОВ И 2,3,4,5-ТЕТРАГИДРОПИРРОЛО [1,2-a][1,4]-ДИАЗЕПИН-7-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ
WO2006029176A3 (fr) Antigenes du cancer du testicule
WO2006019982A3 (fr) Composes modulateurs de pin1 et leurs procedes d'utilisation
WO2006027693A8 (fr) Genes et arn variants specifiques de tumeur et leurs utilisations comme cibles pour le traitement et le diagnostic du cancer
AU2002364501A1 (en) Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
WO2006137938A3 (fr) Fragments d'anticorps assurant la protection contre l'infection par des pathogenes, methodes d'utilisation de ces derniers

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase